NCT04271098 is a clinical trial of Open-Heart Surgery for nine months duration in Hyperbilirubinemia, sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital.

Who is sponsoring NCT04271098?

NCT04271098 is sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital.

What drugs are being tested in NCT04271098?

Interventions in NCT04271098: Open-Heart Surgery for nine months duration, Relation between possible risk factors and hyperbilirubinemia, Follow-up period.

What condition does NCT04271098 study?

NCT04271098 studies Hyperbilirubinemia, Hepatic Impairment, Surgery, Cardiac Disease.

Is NCT04271098 still recruiting?

NCT04271098 is currently completed. Last updated 20 February 2020.

Last reviewed 2020-02-20 · How we verify

NCT04271098

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries

Completed Last updated 20 February 2020

What this trial tests

trial testing Open-Heart Surgery for nine months duration in Hyperbilirubinemia in 340 participants. Completed in 1 September 2012.

Timeline

1 January 2012

Primary endpoint
1 July 2012

1 September 2012

Quick facts

Lead sponsor	Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	340
Start date	1 January 2012
Primary completion	1 July 2012
Estimated completion	1 September 2012

Drugs / interventions tested

Open-Heart Surgery for nine months duration
Relation between possible risk factors and hyperbilirubinemia
Follow-up period

Conditions studied

Hyperbilirubinemia — all drugs for Hyperbilirubinemia →
Hepatic Impairment — all drugs for Hepatic Impairment →
Surgery — all drugs for Surgery →
Cardiac Disease — all drugs for Cardiac Disease →

Sponsor

Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

Who can join

Adults 19 to 80, any sex, with Hyperbilirubinemia or Hepatic Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a prospective observational study during the six-month duration, coronary artery bypass graft surgery (CABG) and valve repair surgery (mitral, mitral, and aortic valve and/or tricuspid valve) patients were investigated for hepatic dysfunction. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. Our goal was to determine the risk factors associated with hepatic dysfunction in patients undergoing open-heart surgery with cardiopulmonary bypass. The collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days 1, 3 and 7. Possible preoperative, intraoperative, and postoperative risk factors were investigated. Logistic regression analysis was done to identify the risk factors for postoperative hyperbilirubinemia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Investigation of Risk Factors Related to the Development of Hepatic Dysfunction in Patients with a Low and Moderate Cardiac Risk During Open-Heart Surgeries.
Baysal A, Sagiroglu G, Dogukan M, Ozkaynak I. · · 2021 · cited 2× · PMID 34048203 · DOI 10.21470/1678-9741-2019-0427

Verify or expand the search:

Other recruiting trials for Hyperbilirubinemia

Currently open trials in the same condition.

NCT06421844 — A Prospective Study: Smart Phone Application for Measure Serum Bilirubin Through Sclera Images · recruiting

Other Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital trials

Trials by the same sponsor.

NCT07467941 — Impact of Visceral Adiposity on Postoperative Atrial Fibrillation After CABG · not yet recruiting
NCT07390903 — GLS in Difficult CPB Weaning · recruiting
NCT06387095 — Efficacy of Parasternal Blocks in Cardiovascular Surgery Patients Undergoing Median Sternotomy · NA · recruiting
NCT06191913 — Microcirculatory Alteration by a Vascular Occlusion Test Using Near-infrared Spectroscopy in Pediatric Cardiac Surgery · completed
NCT03806504 — High PEEP Application Following Pulmonary Thromboendarterectomy; Does it Have Any Impact on Outcome? · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04271098 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Last refreshed: 20 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04271098.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing